Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best dose of BH-30236 to treat people with leukemia. This study includes people with acute myelogenous leukemia (AML) that relapsed (came back) after treatment. It also includes people with higher-risk myelodysplastic syndrome (MDS). Higher-risk means a disease has a higher chance of coming back or not responding to standard treatment.
In this study, researchers want to find the best dose of XmAb819 to treat kidney cancer. The people in this study have clear cell renal cell cancer that keeps growing or came back after standard treatments.
Researchers are comparing combination chemotherapy alone or with a stem cell transplant for people with amyloid light chain (AL) amyloidosis. The people in this study have newly diagnosed AL amyloidosis. The chemotherapy includes daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD).
Researchers want to find the best dose of FOG-001 to use in people with advanced cancer. This study focuses on people who have colorectal and other digestive cancers that spread and keep growing after treatment.
Researchers are assessing the iberdomide with belantamab mafodotin and dexamethasone in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even with treatment.
Researchers are comparing treatment with doxorubicin chemotherapy and pembrolizumab immunotherapy to doxorubicin alone for advanced sarcoma. The people in this study have undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. Their cancers have metastasized (spread) or are inoperable (cannot be taken out with surgery).
The transplantation of stem cells from umbilical cord blood is a treatment for some blood cancers and non-cancerous blood or metabolic disorders. Patients routinely receive high doses of chemotherapy and sometimes radiation before receiving the stem cells to help make room in the bone marrow for new blood stem cells to grow, prevent the body from rejecting the transplanted cells, and help kill any abnormal blood cells in the body. However, the combination of these treatments can have serious side effects.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments often do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).
In this study, researchers are finding the highest dose of MQ710 to use safely in people with certain types of advanced cancer. The people in this study have solid tumors that came back or grew even after treatment. In a later part of the study, the researchers will assess MQ710 plus another drug called pembrolizumab.
Researchers are assessing the cellular therapy lisocabtagene maraleucel (liso-cel) in people with primary central nervous system lymphoma (PCNSL). The people in this study have PCNSL that has not yet been treated. In addition, they cannot have autologous stem cell transplantation (ASCT). During ASCT, a patient's healthy, blood-forming cells are collected before treatment, stored, and returned after treatment with very strong chemotherapy.
